Functional MRI in neurodegenerative disease

Top
Oral presentation

2003 Annual Meeting of the Arbeitsgemeinschaft für Angewandte Humanpharmakologie (Association for Applied Human Pharmacology)

Viewing options:

Abstract

Related literature:

Articles citing this article
on Google Scholar
Other articles by authors
on Google Scholar

Gilles C

on PubMed

Gilles C
Related articles/pages
on Google

on Google Scholar

Tools:

Post to:

Oral presentation

Functional MRI in neurodegenerative disease

Christian Gilles^†

FORENAP; Rouffach, France

author email† Presenting author

2003 Annual Meeting of the Arbeitsgemeinschaft für Angewandte Humanpharmakologie (Association for Applied Human Pharmacology)
Bonn, Germany, 23-25 February 2003

AGAH 2003, 2:op020

Received:	27 March 2003
Published:	28 April 2003

Oral presentation

Because most of neurodegenerative diseases are of unknown etiology, any concept underlying drug development is uncertain in nature. Besides symptomatic treatment, the ultimate goal is to reverse some pathophysiological processes -such as beta-amyloid load in Alzheimer's disease- in identified patients and to prevent disease in at-risk individuals. With current drug development schemes, it requires long term clinical studies in large patients samples. Magnetic resonance techniques (structural imaging, functional imaging, spectroscopy) afford various approaches in the study of degenerative diseases. They could also provide surrogate markers of the effects of drugs, making development more secure and faster.

Functional MRI in neurodegenerative disease

Oral presentation

Have something to say? Post a comment on this article!